ArticleBiochemistry and biophysics reports2026
Clinical pathological changes in prostate cancer patients after hormonal therapy: A single-center pilot study.
Article in Biochemistry and biophysics reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Prostate cancer (PCa) remains a leading malignancy with variable prognosis, and while PSA is widely used for disease monitoring, it frequently lacks sufficient specificity. This study investigated plasma coagulation parameters, inflammatory cytokines, and molecular markers as complementary biomarkers in PCa patients undergoing hormonal therapy. Methods: In a prospective single-center pilot study, patients with newly diagnosed PCa were evaluated alongside patients with benign prostatic hyperplasia (BPH) and healthy men as controls. Coagulation parameters (PT, INR, APTT, fibrinogen, D-dimer), inflammatory cytokines (IFN-γ, IL-1β, TGF-β), and gene expression of p53 and NF-κB were measured before and after six months of hormonal therapy. Statistical analyses included non-parametric tests, ROC curve analysis, Firth penalized logistic regression adjusted for age, tumor grade, and PSA, and internal validation via 5-fold cross-validation and 1000-iteration bootstrapping. Results: PCa patients exhibited a hypercoagulable state, with elevated IL-1β, p53, and NF-κB, alongside reduced IFN-γ and TGF-β, compared with BPH and healthy controls. Hormonal therapy partially reversed these alterations toward values observed in the BPH and healthy control groups. ROC analysis demonstrated high discriminatory potential for IL-1β and NF-κB (AUC = 1.000) in the full dataset; however, this likely reflects near-perfect group separation in a small cohort (n = 32 PCa). Internal validation via 5-fold cross-validation and 1000-iteration bootstrapping yielded a corrected mean AUC of 0.725 (95% CI: 0.58-0.87), which is the primary performance estimate reported. Conclusion: Coagulation disturbances, cytokine imbalance, and alterations in molecular markers are closely associated with PCa biology and short-term therapeutic response. These findings are hypothesis-generating, and long-term clinical endpoints, including biochemical recurrence and survival, require evaluation in adequately powered, multicenter longitudinal studies before these biomarkers can be considered for clinical integration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.